| Dr John Matthew Hancock, MD | |
|
2001 Inwood Rd, Dallas, TX 75390-1317 | |
| (214) 645-2800 | |
| Not Available |
| Full Name | Dr John Matthew Hancock |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 10 Years |
| Location | 2001 Inwood Rd, Dallas, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104239409 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | S5381 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ut Southwestern University Hospital - William P. Clements Jr. | Dallas, TX | Hospital |
| Parkland Health & Hospital System | Dallas, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Texas Southwestern Medical Center | 0648188250 | 2588 |
News Archive
A research team led by Paul Marasco, Ph.D., of Cleveland Clinic's Lerner Research Institute, has won a $2.5 million contract from the Defense Advanced Research Projects Agency. The contract was awarded through DARPA's new Hand Proprioception and Touch Interfaces (HAPTIX) program, which aims to deliver naturalistic sensations to amputees and enable better control over their prosthetic limbs through direct connections to users' nervous systems.
While the world has its eyes on vaccines to stop the spread of coronavirus, therapeutics are still necessary to treat hospitalized patients. One of these treatments, remdesivir, is the first and only antiviral agent of its kind that the U.S. Food and Drug Administration (FDA) has approved so far for COVID-19.
Molina Healthcare, Inc. today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. In connection with the offering, Molina Healthcare and the selling stockholder intend to grant the underwriters an option to purchase up to 350,000 shares and 250,000 shares, respectively, to cover overallotments, if any. The offering is being conducted pursuant to an effective registration statement filed with the Securities and Exchange Commission on December 8, 2008.
In prostate cancer, estimates of lead time (how long screening advances diagnosis of cancer) and overdiagnosis (the fraction of cancers detected by screening that would not have been diagnosed during the patient's lifetime without screening) vary widely, depending on the definition of lead time used, the population, and the estimation methodology, according to a report in the March 10 online issue of the Journal of the National Cancer Institute.
› Verified 9 days ago
| Entity Name | University Of Texas Southwestern Medical Center At Dallas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972579365 PECOS PAC ID: 0648188250 Enrollment ID: O20031106000792 |
News Archive
A research team led by Paul Marasco, Ph.D., of Cleveland Clinic's Lerner Research Institute, has won a $2.5 million contract from the Defense Advanced Research Projects Agency. The contract was awarded through DARPA's new Hand Proprioception and Touch Interfaces (HAPTIX) program, which aims to deliver naturalistic sensations to amputees and enable better control over their prosthetic limbs through direct connections to users' nervous systems.
While the world has its eyes on vaccines to stop the spread of coronavirus, therapeutics are still necessary to treat hospitalized patients. One of these treatments, remdesivir, is the first and only antiviral agent of its kind that the U.S. Food and Drug Administration (FDA) has approved so far for COVID-19.
Molina Healthcare, Inc. today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. In connection with the offering, Molina Healthcare and the selling stockholder intend to grant the underwriters an option to purchase up to 350,000 shares and 250,000 shares, respectively, to cover overallotments, if any. The offering is being conducted pursuant to an effective registration statement filed with the Securities and Exchange Commission on December 8, 2008.
In prostate cancer, estimates of lead time (how long screening advances diagnosis of cancer) and overdiagnosis (the fraction of cancers detected by screening that would not have been diagnosed during the patient's lifetime without screening) vary widely, depending on the definition of lead time used, the population, and the estimation methodology, according to a report in the March 10 online issue of the Journal of the National Cancer Institute.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Matthew Hancock, MD Po Box 845347, Dallas, TX 75284-5347 Ph: () - | Dr John Matthew Hancock, MD 2001 Inwood Rd, Dallas, TX 75390-1317 Ph: (214) 645-2800 |
News Archive
A research team led by Paul Marasco, Ph.D., of Cleveland Clinic's Lerner Research Institute, has won a $2.5 million contract from the Defense Advanced Research Projects Agency. The contract was awarded through DARPA's new Hand Proprioception and Touch Interfaces (HAPTIX) program, which aims to deliver naturalistic sensations to amputees and enable better control over their prosthetic limbs through direct connections to users' nervous systems.
While the world has its eyes on vaccines to stop the spread of coronavirus, therapeutics are still necessary to treat hospitalized patients. One of these treatments, remdesivir, is the first and only antiviral agent of its kind that the U.S. Food and Drug Administration (FDA) has approved so far for COVID-19.
Molina Healthcare, Inc. today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. In connection with the offering, Molina Healthcare and the selling stockholder intend to grant the underwriters an option to purchase up to 350,000 shares and 250,000 shares, respectively, to cover overallotments, if any. The offering is being conducted pursuant to an effective registration statement filed with the Securities and Exchange Commission on December 8, 2008.
In prostate cancer, estimates of lead time (how long screening advances diagnosis of cancer) and overdiagnosis (the fraction of cancers detected by screening that would not have been diagnosed during the patient's lifetime without screening) vary widely, depending on the definition of lead time used, the population, and the estimation methodology, according to a report in the March 10 online issue of the Journal of the National Cancer Institute.
› Verified 9 days ago
Uma B.r.k Pakkivenkata, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9900 N Central Expy Ste 215, Dallas, TX 75231 Phone: 214-396-4950 Fax: 877-423-5360 | |
Dr. Ariel Marcelo Modrykamien, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3600 Gaston Ave, Wadley Tower, Suite 960, Dallas, TX 75246 Phone: 402-972-6078 | |
Benjamin Seth Martinez, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-3111 Fax: 214-648-5461 | |
Vijaya Mummadi, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9900 N Central Expy Ste 225, Dallas, TX 75231 Phone: 469-646-8880 Fax: 469-646-8884 | |
Dr. Ting-yi Chen, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-645-2800 Fax: 214-645-2808 | |
William Cook Langmade, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1441 N Beckley Ave, Dallas, TX 75203 Phone: 214-947-2306 | |
Dr. Janame J Kottey, MBBS Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 13154 Coit Rd Ste 100, Dallas, TX 75240 Phone: 214-358-2300 Fax: 214-579-6989 |